User menu

Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma.

Bibliographic reference Bauwens, Deborah ; Maerevoet, Marie ; Michaux, Lucienne ; Théate, Ivan ; Hagemeijer, Anne ; et. al. Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma.. In: British journal of haematology, Vol. 131, no. 3, p. 338-40 (2005)
Permanent URL
  1. Cheson B.D., Journal of Clinical Oncology, 17, 1244 (1999)
  2. Chow K.U., Haematologica, 87, 33 (2002)
  3. Fisher R. I., Diffuse Aggressive Lymphoma, 10.1182/asheducation-2004.1.221
  4. Forstpointner R., The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group, 10.1182/blood-2004-04-1323
  5. Ghielmini Michele, Schmitz Shu-Fang Hsu, Cogliatti Sergio, Bertoni Francesco, Waltzer Ursula, Fey Martin F., Betticher Daniel C., Schefer Hubert, Pichert Gabriella, Stahel Rolf, Ketterer Nicolas, Bargetzi Mario, Cerny Thomas, Effect of Single-Agent Rituximab Given at the Standard Schedule or As Prolonged Treatment in Patients With Mantle Cell Lymphoma: A Study of the Swiss Group for Clinical Cancer Research (SAKK), 10.1200/jco.2005.04.164
  6. Howard O. M., Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma: Molecular Complete Responses Are Not Predictive of Progression-Free Survival, 10.1200/jco.20.5.1288
  7. Martinelli Giovanni, Laszlo Daniele, Bertolini Francesco, Pastano Rocco, Mancuso Patrizia, Calleri Angelica, Vanazzi Anna, Santoro Paola, Cavalli Franco, Zucca Emanuele, Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma, 10.1046/j.1365-2141.2003.04586.x
  8. Orchard J., A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease, 10.1182/blood-2002-06-1864
  9. Vandenberghe E., De Wolf-Peeters C., Vaughan Hudson G., Vaughan Hudson B., Pittaluga S., Anderson L., Linch D. C., The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group, 10.1046/j.1365-2141.1997.4693273.x